1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
References (59)
- et al.
Chronic administration of l-methyl-4-phenyl1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates
Neuroscience
(1993) - et al.
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study
Eur. J. Pharmacol.
(1995) - et al.
Evidence for retrograde axonal transport of MPP+ in the rat
Neurosci. Lett.
(1990) - et al.
Role of extracellular calcium ion on 1-methyl-4-phenylpyridine induced sustained exocytosis of endogenous striatal dopamine in vivo
Eur. J. Pharmacol.
(1990) - et al.
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Psychiatry Res.
(1979) - et al.
Nimodipine inhibits (3H)nitroben-zylthioinosine binding to the adenosine transporter in human brain
Eur. J. Pharmacol.
(1993) - et al.
Nimodipine enhances growth and vascularization of neural grafts
Exp. Neurol.
(1989) - et al.
N-Methyl-4-phenylpyridine (MPP+) together with 6-hydroxydopamine or dopamine stimulates Ca-release from mitochondria
FEBS Lett.
(1986) - et al.
Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin
Neurochem. Int.
(1996) - et al.
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Eur. J. Pharmacol. Mol. Pharmacol. Sect.
(1991)
Stable Parkinsonian syndrome and uneven loss of dopamine fibres following chronic MPTP administration in baboons
Neuroscience
(1993)
Selective retention of MPP+ within the monaminergic system of the primate brain following MPTP administration: an in vivo autoradiographic study
Neuroscience
(1991)
Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Neurodegeneration
(1995)
1-Methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-induced parkinsonism in the common marmoset
Neurosci. Lett.
(1984)
Differences in metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects
Life Sci.
(1985)
The mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity, role of intracellular calcium
Arch. Biochem. Biophys.
(1988)
Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey
Neuroscience
(1986)
Do NMDA receptor antagonists protect against MPTP toxicity? Biochemical and immunocytochemical analyses in a mouse model of Parkinson's disease
Brain Res.
(1992)
[3H]Nitrendipine binding sites are decreased in the substantia nigra and striatum of the brain from patients with Parkinson's disease
Brain Res.
(1986)
Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in common marmosets
Brain Res.
(1991)
Potentiation by reserpine and tetrabenazine of brain catecholamine depletions by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant
Neurosci. Lett.
(1988)
Chronic exposure to low doses of MPTP: 1. Cognitive deficits motor asymptomatic monkeys
Brain Res.
(1990)
Dose-dependent destruction of the coeruleus-cortical and the nigrostriatal projections by MPTP
Brain Res.
(1990)
Dopamine-releasing action of 1-methyl-4-phenylpyridinium (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique, dependence on sodium but not calcium
Brain Res.
(1988)
Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons
Brain Res.
(1992)
MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells
Brain Res.
(1990)
Relative sparing in Parkinson's disease of substantia nigra neurons containing calbindin-D28K
Brain Res.
(1990)
Nimodipine attenuates NMDA- and MDMA-induced toxicity of cultured fetal serotonergic neurons: evidence for a generic model of calcium toxicity
A primate model of parkinsonism: selective destruction of dopaminergic neuons in the pars compacta of the substantia nigra byN-methyl-4-phenyl-1,2,3,6-tetryhydropyridine
Cited by (90)
Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin
2019, Journal of Chemical NeuroanatomyCalcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease
2017, Experimental NeurologyCalcium and Parkinson's disease
2017, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Unfortunately, there are no genetic animal models of PD with predictive validity. That said, inhibiting Cav1 channels diminishes the damage induced by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) when given at doses that produce partial loss of SNc DA neurons [38,108–110]. Inhibiting Cav1 channels also protects SNc DA neurons from low doses of the environmental toxin rotenone [38].
Copyright © 1996 Published by Elsevier B.V.